STVN (Stevanato Group SpA) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STVN Stevanato Group SpA STVN
87 GF Score
Price $20.24
GF Value $26.04
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Stevanato Group SpA Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

STVN
87GF Score
Stevanato Group SpA STVN
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Stevanato Group SpA (STVN) Overvalued in 2026?

Based on GuruFocus' analysis, Stevanato Group SpA stock appears to be undervalued. The current stock price of $20.24 is trading 22.3% below its estimated GF Value™ of $26.04. GuruFocus considers Stevanato Group SpA to be Modestly Undervalued.

Key valuation signals for STVN:

  • Dividends Paid:
  • GF Value™: $26.04 vs. price of $20.24 (22.3% below fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the STVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stevanato Group SpA Business Description

Other Exchanges 87N:Germany
Address Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
87GF Score

Get the complete analysis for STVN

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.24
Price
$26.04
GF Value